G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome With Diarrhea (IBS-D) Clinical Trial

Official title:
A Randomized, Placebo Controlled, Double-blind, Parallel-arm Feasibility (Pilot) Study to Evaluate Safety and Clinical Efficacy of G-PUR® Treatment in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Status Recruiting

Clinical Trial Summary

A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g G-PUR® tid compared to placebo in a cohort of 30 patients over an active treatment period of 12 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Diarrhea
Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Syndrome

Clinical Trial Details

NCT number	NCT04138186
Study type	Interventional
Source	Glock Health, Science and Research GmbH
Contact	Michael Wolzt, Prof. Dr.
Phone	+43 (0)1 40400
Email	michael.wolzt@meduniwien.ac.at
Status	Recruiting
Phase	N/A
Start date	October 2, 2019
Completion date	February 2021

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00394173` - Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)	Phase 2
	Completed	`NCT03931785` - A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome	Phase 2